The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2017 | An insight into future treatments for MM and their complications
Nikhil Munshi, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, USA, provides us with an insight into the potential treatments for multiple myeloma (MM) and their justifications. Potential targets detailed by Dr. Munshi include designing antibodies against anti-IL-17 and anti-PD1/PDL1, which could then be combined with immunomodulators such as lenalidomide to augment their therapeutic response. Another potential therapy is the combination of vaccines with lenalidomide, which would hypothetically prolong the drug’s therapeutic effect. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
